Advertisement

Investigational New Drugs

, Volume 25, Issue 1, pp 77–84 | Cite as

Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial

  • Chia-Chi Lin
  • Chiun Hsu
  • Chih-Hung Hsu
  • Wei-Ling Hsu
  • Ann-Lii Cheng
  • Chih-Hsin YangEmail author
Phase II Studies

Summary

Background: Arsenic trioxide induces growth inhibition and apoptosis in human hepatocellular carcinoma (HCC) cell lines. A phase II trial was conducted to evaluate the efficacy and toxicity of single-agent arsenic trioxide in patients with HCC.

Methods: Inclusion criteria included advanced HCC patients to whom no standard palliative treatment can be offered, good organ function and liver function reserve. Patients received arsenic trioxide 0.16–0.24 mg/kg per day for 5–6 days per week for 3–4 weeks, followed by one-week rest. Tumor response was assessed every 2 cycles. Primary endpoint was the percentage of patients with 6-month disease stabilization.

Results: Twenty-nine patients (median age, 59) with locally advanced or metastatic HCC received a total of 61 cycles (median, 2; range, 1–6). One patient had partial response. Three patients had disease stabilization for at least six months. The 6-month tumor stabilization rate was 14% (95% CI, 1–27). The median overall survival was 4.8 months (95% CI, 1.4–8.2) and one-year survival was 30%.

Conclusion: Single-agent arsenic trioxide using this dose schedule is not active against advanced HCC.

Keywords

Antineoplastic agents Arsenic Clinical trials Liver neoplasms 

References

  1. 1.
    Hsu C, Cheng JC, Cheng AL (2004) Recent advances in non-surgical treatment for advanced hepatocellular carcinoma. J Formos Med Assoc 103:483–495PubMedGoogle Scholar
  2. 2.
    Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell RP Jr (1998) Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339:1341–1348PubMedCrossRefGoogle Scholar
  3. 3.
    Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, Wu W, Zhang FQ, Chen Y, Zhou L, Li JM, Zeng XY, Yang RR, Yuan MM, Ren MY, Gu FY, Cao Q, Gu BW, Su XY, Chen GQ, Xiong SM, Zhang TD, Waxman S, Wang ZY, Chen Z, Hu J, Shen ZX, Chen SJ (1999) Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94:3315–3324PubMedGoogle Scholar
  4. 4.
    Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K, Lamph WW, Waxman S, Pelicci PG, Lo CF, Avvisati G, Testa U, Peschle C, Gambacorti-Passerini C, Nervi C, Miller WH Jr (1998) Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 90:124–133PubMedCrossRefGoogle Scholar
  5. 5.
    Oketani M, Kohara K, Tuvdendorj D, Ishitsuka K, Komorizono Y, Ishibashi K, Arima T (2002) Inhibition by arsenic trioxide of human hepatoma cell growth. Cancer Lett 183:147–153PubMedCrossRefGoogle Scholar
  6. 6.
    Zhang T, Wang SS, Hong L, Wang XL, Qi QH (2003) Arsenic trioxide induces apoptosis of rat hepatocellular carcinoma cells in vivo. J Exp Clin Cancer Res 22:61–68PubMedGoogle Scholar
  7. 7.
    Kito M, Matsumoto K, Wada N, Sera K, Futatsugawa S, Naoe T, Nozawa Y, Akao Y (2003) Antitumor effect of arsenic trioxide in murine xenograft model. Cancer Sci 94:1010–1014PubMedCrossRefGoogle Scholar
  8. 8.
    Dai J, Weinberg RS, Waxman S, Jing Y (1999) Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 93:268–277PubMedGoogle Scholar
  9. 9.
    Mathas S, Lietz A, Janz M, Hinz M, Jundt F, Scheidereit C, Bommert K, Dorken B (2003) Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis. Blood 102:1028–1034PubMedCrossRefGoogle Scholar
  10. 10.
    Lew YS, Brown SL, Griffin RJ, Song CW, Kim JH (1999) Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. Cancer Res 59:6033–6037PubMedGoogle Scholar
  11. 11.
    Roboz GJ, Dias S, Lam G, Lane WJ, Soignet SL, Warrell RP Jr, Rafii S (2000) Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 96:1525–1530PubMedGoogle Scholar
  12. 12.
    Qian J, Qin S, He Z (2001) Arsenic trioxide in the treatment of advanced primary liver and gallbladder cancer. Zhonghua Zhong Liu Za Zhi 23:487–489PubMedGoogle Scholar
  13. 13.
    Liaw YF, Tai DI, Chen TJ, Chu CM, Huang MJ (1986) Alpha-fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis and hepatocellular carcinoma. Liver 6:133–137PubMedGoogle Scholar
  14. 14.
    Okuda K (1986) Early recognition of hepatocellular carcinoma. Hepatology 6:729–738PubMedGoogle Scholar
  15. 15.
    American Joint Committe on Cancer (2002) Manual for staging of cancer, 6th edn. Lippincott, PhiledelphiaGoogle Scholar
  16. 16.
    The Cancer of the Liver Italian Program (CLIP) Investigators (1998) A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 28:751–755CrossRefGoogle Scholar
  17. 17.
    Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Seminars in Liver Disease 19:329–338PubMedCrossRefGoogle Scholar
  18. 18.
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216PubMedCrossRefGoogle Scholar
  19. 19.
    Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1–10PubMedCrossRefGoogle Scholar
  20. 20.
    Hsu C, Chen CN, Chen LT, Wu CY, Yang PM, Lai MY, Lee PH, Cheng AL (2003) Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology 65:242–249PubMedCrossRefGoogle Scholar
  21. 21.
    Leung TW, Tang AM, Zee B, Yu SC, Lai PB, Lau WY, Johnson PJ (2002) Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer 94:421–427PubMedCrossRefGoogle Scholar
  22. 22.
    Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, Koh J, Mo FK, Yu SC, Chan AT, Hui P, Ma B, Lam KC, Ho WM, Wong HT, Tang A, Johnson PJ (2005) A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 19(97):1532–1538Google Scholar
  23. 23.
    Barbare JC, Bouche O, Bonnetain F, Raoul JL, Rougier P, Abergel A, Boige V, Denis B, Blanchi A, Pariente A, Milan C, Bedenne L (2005) Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol 23:4338–4346PubMedCrossRefGoogle Scholar
  24. 24.
    Douer D, Tallman MS (2005) Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol 23:2396–2410PubMedCrossRefGoogle Scholar
  25. 25.
    Kim KB, Bedikian AY, Camacho LH, Papadopoulas NE, McCullough C (2005) A phase II trial of arsenic trioxide in patients with malignant melanoma. Cancer 104:1687–1692Google Scholar
  26. 26.
    Vuky J, Yu R, Schwartz L, Motzer RJ (2002) Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma. Invest New Drugs 20:327–330PubMedCrossRefGoogle Scholar
  27. 27.
    Barbey JT, Pezzullo JC, Soignet SL (2003) Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol 21:3609–3615PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2006

Authors and Affiliations

  • Chia-Chi Lin
    • 1
    • 3
  • Chiun Hsu
    • 1
    • 3
  • Chih-Hung Hsu
    • 1
    • 3
  • Wei-Ling Hsu
    • 3
  • Ann-Lii Cheng
    • 1
    • 2
    • 3
  • Chih-Hsin Yang
    • 1
    • 3
    Email author
  1. 1.Department of OncologyNational Taiwan University HospitalTaipeiTaiwan
  2. 2.Department of Internal MedicineNational Taiwan University HospitalTaipeiTaiwan
  3. 3.Cancer Research CenterNational Taiwan University College of MedicineTaipeiTaiwan

Personalised recommendations